| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | June 2, 2025 4:00 P.M. |
| Form: | S-3 | ||||||
| |||||||
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/16/2024 | $28.00 | Buy | H.C. Wainwright |
| 12/13/2024 | $30.00 | Outperform | Robert W. Baird |
| 10/16/2024 | $35.00 | Outperform | Oppenheimer |
| 9/12/2024 | $17.00 | Buy | Guggenheim |
| 7/22/2024 | $13.00 | Outperform | Leerink Partners |
| 6/13/2024 | $30.00 | Overweight | Piper Sandler |
| 2/17/2022 | $10.00 | Buy | HC Wainwright & Co. |
H.C. Wainwright initiated coverage of Benitec Biopharma with a rating of Buy and set a new price target of $28.00
Robert W. Baird initiated coverage of Benitec Biopharma with a rating of Outperform and set a new price target of $30.00
Oppenheimer initiated coverage of Benitec Biopharma with a rating of Outperform and set a new price target of $35.00